PRA IC List
Skip to main content
An official website of the United States government
The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Search:
Agenda
Reg Review
ICR
Information Collection List
IC Title
Status
Responses
Hours
Dollars
Document Type
Form No.
Form Name
Accuracy of Opioid Product Ascertainment (CDER)
Unchanged
96
96
0
Other-Survey Instrument
Other-Consent Form
Other-Interview Guide
Other-Study Design and Protocol
An Exploratory Assessment of Substances Used as Adjuncts or Alternatives to Prescription Opioids
Unchanged
280
210
0
Other-Screener
Other-List of Prescription Opioids
Other-List of Prescription Benzodiazepines
Other-Consent Form
Other-Reminder
Other-Interview Guide
Other-Certificate of Confidentiality
Assessment of a Pharmacist-Led Transition of Care Service Utilizing an Admissions Enhanced, Patient Risk Evaluation Approach: the ICARE Program
Unchanged
450
37
0
Other-Survey Instrument: Consent Form
Other-Survey Instrument: Pre-implementation Provider Perception and Demand Survey
Other-Survey Instrument: 12- and 18-month Provider Survey
Other-Other: Signed IRB Approval
Attitudes and Perceptions of People Living with Hepatitis B on Participation in Clinical Trials
New
2000
1000
0
Other-Advertisement Africa 1
Other-Advertisement Africa 2
Other-Advertisement Africa 3
Other-Advertisement African T
Other-Advertisement All Audiences 1
Other-Advertisement All Audiences 2
Other-Advertisement All Audiences 3
Other-Advertisement All Audiences T
Other-Advertisement Asian T
Other-Advertisement Asian
Other-Advertisement Eastern Europe
Other-Advertisement India T
Other-Advertisement India
Other-Advertisement Middle East T
Other-Advertisement Middle East
Other-Emal invitation
Other-Online invitation
Other-Survey-Amharic
Other-Survey-Chinese
Other-Survey-English
Other-Survey-French
Other-Survey-Korean
Other-Survey-Marshallese
Other-Survey-Spanish
Other-Survey-Tagalog
Other-Survey-Vietnamese
Other-IRB
Collection of Data to Support Training Decay Selection for Medical Product Usability Validation Testing (CDER)
Unchanged
139
348
0
Other-Moderator Script
Other-Initial Training Script
Other-Consent Forms
Other-Protocol
Other-post-survey questionnaire
Improving FDA Health Communications with Older Women Regarding FDA-Regulated Products (CDER)
Unchanged
192
384
0
Other-Consent Form
Other-Script
Other-Reminder Email
Other-Drug Safety Health Communication Tool
Other-Moderator Guide
Other-Guide on Medicine
Other-Screenshot of CDER Communications
Other-Screenshot of Vaccine Communication
Other-Medication Risk and Benefit Brochure
Other-Survey Instrument
Improving the Quality and Representativeness of the Treatment Center Program Data: Survey to Quantify the Magnitude of Misclassification of Opioid Product Identification (CDER)
Unchanged
1100
275
0
Other-Survey Instrument
Multistate Pharmacist Survey for Methodologic Advances in Evaluating Abuse Deterrent Opioid Analgesics (CDER)
Unchanged
2500
250
0
Other-Questionnaire
Other-Email Invitation and Cover Letter
Multistate Pharmacist Survey for Methodologic Advances in Evaluating Abuse Deterrent Opioid Analgesics (Maryland)
Unchanged
1200
120
0
Other-Survey
Other-Survey
NMURx Express Survey to Evaluate Stimulant Abuse in the United States: Trajectories from Medical Use to Non-Medical Use (CDER)
Unchanged
1400
233
0
Other-Questionnaire
Other-Consent Form
Other-Certification of Confidentiality
Perioperative Medication Safety Self-Assessment for Hospitals and Ambulatory Surgical Centers and Targeted Risk-Reduction Tool Development (CDER)
Unchanged
1500
11171
0
Other-Survey Instrument
Other-Screenshot Webpage
Prescriber Decision-Making about Pain Management and Opioid Prescribing
New
20
12
0
Other-E-mail invitation
Other-Verbal consent form
Other-Semi-structured interview protocol
Other-IRB exemption
Preventable Harm from Outpatient Pediatric Medication Errors: Measure Development
New
225
240
0
Other-Org Leader Interviews Recruitment Email
Other-Idea Generation Recruitment Email
Other-Rating and Feasibility Recruitment Email
Other-Org Leader Interview Guide
Other-Idea Generation Questionnair
Other-Parent Interview Guide
Other-Sorting Measures Type Idea Recruitment Email
Other-Screenshots-Sorting of Measure Type Ideas
Other-Rating Sheet
Other-IRB Correspondence
Quantitative Claims in Direct-to-Consumer Prescription Drug Advertising: Consumer Interviews
New
80
36
0
Other-Interview guide
Other-Consent form
Other-Recruitment email
Other-Screener
Risk Evaluation and Mitigation Strategy (REMS) Programs to Promote Appropriate Medication Use and Knowledge: Physician Experiences with REMS Programs (CDER)
Unchanged
1200
400
0
Other-Invitation
Other-Consent Form
Other-Survey - Ambrisentan
Other-Survey - Bosentan
Other-Survey - Clozapine
Other-Survey - Isotretinoin
Other-Survey - Lenalidomide-Pomalidomide-Thalidomide
Other-Survey - Sodium Oxybate
Other-Reminder Letter
Other-IRB Letter
Risk Evaluation and Mitigation Strategy (REMS) Programs to Promote Appropriate Medication Use and Knowledge: Physician Experiences with REMS Programs (CDER)
Unchanged
1420
0
0
Other-Patient Guide
Other-Recruitment Messages-Email
Other-Recruitment Messages-Email Forward-Patient and Caretaker
Other-Recruitment Messages-Email-Patient Only
Other-Recruitment Messages-Email-Patient or Caretaker
Other-Recruitment Messages-Rally
Other-Recruitment Messages-Rally-Patient Only
Other-Recruitment Messages-Rally-Patient or Caretaker
Other-Patient Interview-Alvimopan Guide
Other-Fact Sheet
Other-Physician Survey - Ambrisentan
Other-Physician Survey-Bosentan
Other-Physician Survey-Clozapine
Other-Physician Survey-Isotretinoin
Other-Physician Survey-Lenalidomide-Pomalidomide-Thalidomide
Other-Physician Survey-Sodium Oxybate
Risk Evaluation and Mitigation Strategy Programs to Promote Appropriate Medication Use and Knowledge: Patient Experiences with REMS Programs (CDER)
Unchanged
160
160
0
Other-Interview Guide
Other-Consent Form
Other-Recruitment Message-Email-All Drugs-Patient Only
Other-Recruitment Message-Email-Patient or Caretaker
Other-Recruitment Message-Email Forward- Patient Only
Other-Recruitment Message-Email Forward-Patient or Caretaker
Other-Recruitment Message-Rally-All Drugs-Patient Only
Other-Recruitment Message-Rally-C and P - Patient Only
Other-Recruitment Research Match-All Drugs - Patient Only
Other-Recruitment Research Match-Patient or Caretaker
Other-Drug Specific Content
Other-IRB Letter
Risk Evaluation and Mitigation Strategy Programs to Promote Appropriate Medication Use and Knowledge: Physician Interviews on Experiences with REMS Programs (CDER)
Unchanged
60
60
0
Other-Recruitment Message - Physicians
Other-Recruitment Message - Professional Society
Other-Consent
Other-Interview Guide - Alemtuzumab
Other-Alvimopan
Other-Interview Guide - Pegvaliase
Other-IRB Letter
Training Decay for Medical Products: Insulin Pump Usability Study (CDER)
Unchanged
150
285
0
Other-Initial Training Script
Other-Moderators Script
Other-End of Study Questionnaire
Other-Informed Consent
Other-IRB Letter
Total Burden Actually Used for Information Collections Under Currently Approved ICR:
14172
15317
0
Total Burden Currently Requested for Information Collections Under Currently Approved ICR:
0
0
0
To view an IC, click on IC Title